THERMO FISHER SCIENTIFIC INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that THERMO FISHER SCIENTIFIC INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $6.05B | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $5.12B | Feb 28, 2018 |
| FY2017 | Jul 1, 2017 | $4.99B | Feb 28, 2018 |
| FY2017 | Apr 1, 2017 | $4.77B | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $4.95B | Feb 28, 2018 |
| FY2017 | Oct 1, 2016 | $4.49B | Feb 28, 2018 |
| FY2017 | Jul 2, 2016 | $4.54B | Feb 28, 2018 |
| FY2017 | Apr 2, 2016 | $4.30B | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $4.65B | Feb 28, 2017 |
| FY2016 | Sep 26, 2015 | $4.12B | Feb 28, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.56B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $42.88B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $42.86B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $44.92B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $39.21B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $32.22B | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $6.83B | Feb 26, 2020 |
| FY2019 | Sep 28, 2019 | $6.27B | Feb 26, 2020 |
| FY2019 | Jun 29, 2019 | $6.32B | Feb 26, 2020 |
| FY2019 | Mar 30, 2019 | $6.13B | Feb 26, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $3.04B | Feb 26, 2020 |
| FY2019 | Sep 28, 2019 | $2.76B | Feb 26, 2020 |
| FY2019 | Jun 29, 2019 | $2.82B | Feb 26, 2020 |
| FY2019 | Mar 30, 2019 | $2.71B | Feb 26, 2020 |
| FY2018 | Dec 31, 2018 | $2.92B | Feb 27, 2019 |
| FY2018 | Sep 29, 2018 | $2.62B | Feb 27, 2019 |
| FY2018 | Jun 30, 2018 | $2.74B | Feb 27, 2019 |
| FY2018 | Mar 31, 2018 | $2.58B | Feb 27, 2019 |
| FY2017 | Dec 31, 2017 | $2.67B | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $2.30B | Feb 28, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.70B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.34B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $6.00B | Feb 26, 2026 |
| FY2013 | Dec 31, 2013 | $342.10M | Feb 27, 2014 |
| FY2013 | Sep 28, 2013 | $317.60M | Feb 27, 2014 |
| FY2013 | Jun 29, 2013 | $277.40M | Feb 27, 2014 |
| FY2013 | Mar 30, 2013 | $336.20M | Feb 27, 2014 |
| FY2013 | Dec 31, 2012 | $376.40M | Feb 27, 2014 |
| FY2013 | Sep 29, 2012 | $290.40M | Feb 27, 2014 |
| FY2013 | Jun 30, 2012 | $233.80M | Feb 27, 2014 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.75B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.34B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $6.86B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $8.39B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $10.03B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $7.79B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $4.59B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $3.78B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $2.96B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $2.46B | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.39B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.34B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.47B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.41B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.18B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.00B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $967.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $887.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $754.00M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.73B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.60B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $8.45B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $8.99B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $8.01B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $6.93B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $6.14B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $6.06B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $5.50B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $4.97B | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.82B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.67B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $8.41B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $9.15B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $9.31B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $8.29B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $4.97B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $4.54B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $4.01B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $3.26B | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.40B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.48B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.24B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.52B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.47B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $926.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $758.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $508.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $444.00M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.34B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $97.32B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $98.73B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $97.15B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $95.12B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $69.05B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $58.38B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $56.23B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $56.67B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $45.91B | Feb 27, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.41B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $49.58B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $46.74B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $43.98B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $40.79B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $34.51B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $29.68B | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | $27.59B | Feb 25, 2021 |
| FY2020 | Dec 31, 2017 | $25.41B | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $21.54B | Feb 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.36B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $45.85B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $44.02B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $41.20B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $41.92B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $26.04B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $25.71B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $25.35B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $25.29B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $21.33B | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.16B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $53.10B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $47.36B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $41.91B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $35.43B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $28.12B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $22.09B | Feb 25, 2021 |
| FY2019 | Jan 1, 2019 | $18.70B | Feb 26, 2020 |
| FY2019 | Dec 31, 2018 | $18.70B | Feb 26, 2020 |
| FY2019 | Jan 1, 2018 | $16.03B | Feb 26, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.85B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.01B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $8.08B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $8.52B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $4.48B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $10.33B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.40B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.10B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.34B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $786.00M | Feb 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.17B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $31.07B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $34.73B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $34.28B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $34.67B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $21.73B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $17.75B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $18.99B | Feb 26, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 16 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 15 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 17 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 19 | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 16 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 2 | Feb 26, 2020 |
| FY2019 | Sep 28, 2019 | 1 | Feb 26, 2020 |
| FY2019 | Jun 29, 2019 | 2 | Feb 26, 2020 |
| FY2019 | Mar 30, 2019 | 2 | Feb 26, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 16 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 15 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 17 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 19 | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 15 | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | 2 | Feb 26, 2020 |
| FY2019 | Sep 28, 2019 | 1 | Feb 26, 2020 |
| FY2019 | Jun 29, 2019 | 2 | Feb 26, 2020 |
| FY2019 | Mar 30, 2019 | 2 | Feb 26, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $636.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $583.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $523.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $455.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $395.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $337.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $297.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $266.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $237.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $238.00M | Feb 27, 2019 |